Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC01-HER2 in HER2-positive solid tumors
NCT04727151Phase 2Terminated
- Sponsor
- Triumvira Immunologics
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of fencabtagene autoleucel in solid tumor, gastric cancer (GC), gastroesophageal junction cancer, sponsored by Triumvira Immunologics. Started Apr 2021; status: terminated.
02
Drugs
fencabtagene autoleucel
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04727151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727151.